ClinicalTrialsFinder
RecruitingPhase 2NCT06742463

VHAG in Treating R/R T-ALL/LBL

Venetoclax Combined With HAG Regimen in Treating Adult Relapse/Refractory Acute T Cell Lymphoblastic Leukemia/Lymphoma: A Phase II, Single Arm and Multicenter Study

Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment

50 participants

Start Date

Dec 1, 2024

Study Type

INTERVENTIONAL

Conditions

Acute T Lymphpblastic Leukemia/Lymphoma

Summary

Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages. After induction chemotherapy and consolidation chemotherapy, there are still about 30% of patients who cannot achieve complete remission of clinical symptoms or negative MRD. This is also an important factor for the recurrence of ALL patients. In addition, most relapsed T-ALL/LBL patients relapse during first-line treatment. Once the disease relapses, it is difficult to cure for most young and adult patients, and the overall survival rate of patients is less than 10%.

Eligibility

Min Age: 14 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new chemotherapy combination called VHAG for people with relapsed or refractory T-cell acute leukemia or lymphoma (cancers of T-cells that have come back or stopped responding to prior treatment). **You may be eligible if...** - You are 14 to 74 years old - You have been diagnosed with T-cell acute leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has relapsed or is no longer responding to treatment - You are in reasonably good physical condition - Your expected survival is at least 2 months - Your organ function is adequate **You may NOT be eligible if...** - Your leukemia/lymphoma has spread to the brain or spinal fluid - You have severe heart, liver, kidney, or lung problems - Your heart pumping function (LVEF) is below 45% - You have had another cancer in the past 5 years (except certain skin cancers) - You have HIV Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVenetoclax

BCL-2 inhibitor

DRUGhomoharringtonine

alkaloid

DRUGCytarabine (Ara-C)

Metabolic antagonist.

DRUGG-CSF

Granulocyte colony-stimulating factor

Locations(1)

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06742463